At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
FRAX 1940 nm laserdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of a Nonablative Fractional 1940 nm Diode Laser for Treatment of Pigmented Lesions
In Brief
A clinical study evaluating FRAX 1940 nm laser for Pigmented Skin Lesion. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study is being conducted to evaluate the safety and efficacy of a fractional diode laser for treatment of pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sunspots), and ephelides (freckles).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPigmented Skin Lesion
CountriesUnited States
CollaboratorsMiami Dermatology and Laser Institute
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedDec 17, 2019
Enrollment StartJan 9, 2020
Primary CompletionApr 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.5 years ago
Interventions
FRAX 1940 nm laserdevice
A fractional 1940 nm solid-state diode laser will deliver linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin, in order to treat pigmented skin lesions.